The US FDA approved the first single-dose generic treatment for influenza, a rival to Genentech’s Xofluza from Norwich Pharmaceuticals, in time for the 2026-2027 flu season.
The US FDA approved the first single-dose generic treatment for influenza, a rival to Genentech’s Xofluza from Norwich Pharmaceuticals, in time for the 2026-2027 flu season.